BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, March 21, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

March 9, 2011

View Archived Issues

Microbicide vaginal gel containing C2F5/C4E10/C2G12 MAbs for HIV-1 is safe in phase I trial

Read More

Renovo discloses exploratory analysis data on Juvista and announces restructuring

Read More

Gemtuzumab ozogamicin improves survival of patients with AML and favorable cytogenetics

Read More

Lilly submits application seeking additional indication for Zyprexa in Japan

Read More

European orphan drug status for Talecris' human plasmin in acute peripheral arterial occlusion

Read More

Multiple-antigen MVA/DNA HIV vaccine regimen is safe and immunogenic in phase I trial

Read More

EMA accepts Insmed's pediatric investigation plan for Arikace

Read More

Vanda Pharma's tasimelteon receives European orphan drug status in N24HSWD

Read More

FDA accepts for review dapagliflozin NDA for type 2 diabetes

Read More

Inovio begins phase II VGX-3100 vaccine program for cervical dysplasia caused by HPV

Read More

New lysophospholipid S1P1 receptor agonists reported by Bristol-Myers Squibb

Read More

Amgen acquires BioVex

Read More

Primary endpoint met in phase II trial of inhaled bimosiamose in COPD

Read More

Amira Pharma describes salts of a prostanoid DP2 receptor antagonist

Read More

Downregulated FGFR-3 expression predicts poor outcome of pancreatic islet cell tumors

Read More

Concert Pharma prepares new deuterated PGI2 receptor agonists

Read More

GSK patents new activators of Toll-like receptor 7 and/or 8

Read More

Novel inhibitors of HCV RNA replication designed at Tibotec

Read More

New topiramate label warns for risk of oral clefts in newborns

Read More

AstraZeneca and Galderma to develop dermatological therapies

Read More

Novartis Diagnostics to market Grifols' immunohematology diagnostics in U.S.

Read More

Kaletra label changed due to health risks in premature babies

Read More

FDA committee recommends approval of QAB-149 to treat airflow obstruction in COPD

Read More

Amsterdam Molecular Therapeutics receives grant to develop AMT-080 for Duchenne's muscular dystrophy

Read More

Phosphorylated forkhead box protein O1 has prognostic value in pancreatic ductal adenocarcinoma

Read More

Popular Stories

  • Today's news in brief

    BioWorld
  • Art concept for targeting the brain

    Precision psychiatry beyond, or before, biomarkers

    BioWorld
    There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
  • MRI image brain on black background

    ADPD 2026: Can we prevent dementia? Scientists quantify it

    BioWorld
    Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
  • Illustration of a motor neuron

    Keros reports beneficial effects of RKER-065 in ALS model

    BioWorld Science
    Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
  • First-in-class POLG activator restores mtDNA across mutations

    BioWorld Science
    Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing